Nine-month sales growth in Russia offset Stada's decline in Serbia

 
• By Maria Bailey
  
Generate a summary of this article
Listen to this article
Beta

Stada, one of the largest Germany-based wholesalers, increased its sales by 3% to €1.2 billion in the first nine months of this year. The company attributed its modest performance mainly to liquidity problems of its subsidiaries in Serbia, one of its most important individual markets. These problems resulted from hospitals' non-payments and/or delayed payments to wholesalers.

Stada, one of the largest Germany-based wholesalers, increased its sales by 3% to €1.2 billion in the first nine months of this year. The company attributed its modest performance mainly to liquidity problems of its subsidiaries in Serbia, one of its most important individual markets. These problems resulted from hospitals' non-payments and/or delayed payments to wholesalers.

Stada wholly owns Hemofarm, the largest pharmaceutical manufacturer in Serbia, and through Hemofarm has a stake in Velefarm, the largest...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.